Navigation Links
Mutation database helps personalized treatment of lung cancer
Date:4/25/2008

A groundbreaking free tool to help oncologists choose the best therapies for patients with non-small-cell lung cancer has been launched this week by scientists at the 1st European Lung Cancer Conference jointly organized by the European Society for Medical Oncology (ESMO) and the International Association for the Study of Lung Cancer (IASLC) in Geneva, Switzerland.

The online database brings together data on all the known somatic mutations (tumor derived - tumor specific) in a molecule called epithelial growth factor receptor (EGFR). Somatic mutations in this cell-surface molecule are known to affect treatment with the newer tyrosine kinase inhibitor class of drugs.

"We have known for some time that some EGFR mutations correlate with response to tyrosine kinase inhibitors for lung cancer patients," says Dr. Samuel Murray from Department of Molecular Pathology and Translational Oncology, Metropolitan Hospital, Athens, Greece. "But there have been so many articles published on this topic that we felt that it would be virtually impossible for any given center or individual to interpret the clinical relevance of a given mutation."

"So we worked on the assumption that a comprehensive list of all somatic EGFR mutations coupled with data on the response of non-small-cell lung cancers treated with tyrosine kinase inhibitors (TKIs) would help clinicians determine whether a specific mutation was likely to correlate with clinical benefit."

The database includes cumulative data from thousands of patients. In addition, independent patient data (IPD) for patients who have been treated with tyrosine kinase inhibitors and some who have not, is being added. A total of 12,244 patients are included, of whom 3,381 had somatic mutations in EGFR. The researchers catalogued 254 different mutations.

Ultimately, the database offers a chance to improve treatment for people receiving tyrosine kinase inhibitors. "We believe that for the more c
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Mutation in human gene helps protect against fatal malaria
2. Breast cancer risk amplified by additional genes in combo with BRCA mutation
3. Different mutations in single gene suggest Parkinsons is primarily an inherited genetic disorder
4. Gene Mutations for Rare Heart Disease Also Found in Kids
5. Researchers Find Gene Mutation That Increases Asthma Risk
6. Rare Gene Mutation Plays Role in Longevity
7. Einstein researchers discover gene mutations linked to longer lifespans
8. Genetic mutation found in peripheral artery disease
9. 2 Mutations Were Critical to Spread of 1918 Flu
10. Single Mutation in Mitochondrial DNA Weakens Heart, Muscles
11. Benefit of cancer prevention surgery differs between women with BRCA1 and BRCA2 mutations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...rter financial results -, LAVAL, QC, July 25 /PRN...DAQ: DDSS) today announced that it will host a con... to discuss its second quarter 2008,financial resu... financial,results via news release at approximate...nce call by telephone, dial 416-646-3095 or,1-800-...
(Date:7/25/2008)...erweight or obese is not only a personal issue tha... issue that impacts other people in society. A new...eveals that the extra Medicare cost associated wit...ant financial burden on tax payers, costing up to ...current Medicare population. , The article,s fi...
(Date:7/25/2008)...Fourth Annual Physician On-Call Pay ...swire/ -- Sullivan, Cotter and Associates, Inc.,ha...on-call pay rates and,practices, the 2008 Physicia...th data from 132 healthcare organizations nationwi...ates paid for 33 physician specialty areas along,w...
(Date:7/25/2008)...ire/ -- Sagent Pharmaceuticals, Inc.,a privately-...nced that it,has launched amiodarone HCl injection...e treatment and prophylaxis of frequently recurrin...table ventricular,tachycardia -- a potentially lif...arone HCl injection will be available immediately ...
Breaking Medicine News(10 mins):Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
...imed in treating AIDS patients using a herbal conc...se in white blood cell count. // Dr P L Meenakshi... reporters that the Herbal medicine helped HIV pa...(lymphocyte 4 - white blood cell) count increased ...
...lous kitten, when it comes to protecting her hands...f young ladies who drape themselves all over the r...at she would rather quit singing forever than lose...she gets really annoyed when girls flirt with her ...
...ded a grant of $30,000 to Medical College of Georg...understand the usefulness of online information sy...hether an online information system woulc be helpu...G was among 60 institutions invited to apply and t...
...essor and director of research in Virginia Commonw...ne reported that it will be fruitful // and more l...oving the medical facilities and provided the exis...ress allocates funds to the National Institute of ...
Other Medicine News:Health News:Online information system for patients 2Health News:Stop spending on new treatments; allocate funds to improve the existing treatments. 2
(Date:7/23/2008)... WASHINGTON, July 23 /PRNewswire-USNewswire/ --... of Justice:, Chairman Conyers, Ranking Member Sm...he opportunity to testify today., Since I appeare...ave,become even better acquainted with the talente...tment and with the work they do, and I have come t...
(Date:7/23/2008)... ASPS Study Finds Some Areas of the Body Have G...IGHTS, Ill., July 23 /PRNewswire-USNewswire/ -- Fa...hrough liposuction was found to be,an excellent so...ations,than other areas of the body, reports a Bra...ructive Surgery(R), the official medical journal o...
(Date:7/23/2008)... SEATTLE, July 23 /- Den... that it expects the Independent Data,Monitoring C...rim analysis,of overall survival relating to the C...e AdenoCarcinoma Treatment, also known as D9902B) ...ENGE is the Company,s investigational,active cellu...
(Date:7/22/2008)... BRISBANE, Australia, July 22 /PRNewswire-First...d late yesterday, the Board of Progen,Pharmaceutic...ed that it,had discontinued the PI-88 phase 3 stud...direction to develop its existing portfolio of com...re additional compounds and,opportunities through ...
Breaking Medicine Technology:Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 2Prepared Remarks of Attorney General Michael B. Mukasey Before the House Judiciary Committee 3Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 2Progen Terminates PATHWAY Trial & Confirms Focus on Potential High Value Molecules and M&A 3Looking at neurons from all sides 3069 1Looking at neurons from all sides 3069 2deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 1deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 2deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 3deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 4deCODE Discovers Fourth Major Set of Common Genetic Variants Linked to Risk of Estrogen Receptor Positive Breast Cancer 4893 5Therap Services to Host Conference in Association with the Delaware Division of Developmental Disabilities Services 17817 1Therap Services to Host Conference in Association with the Delaware Division of Developmental Disabilities Services 17817 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 1Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment Naive Hepatitis C Patients Presented At EASL 1901 9
...DNEY, Australia, March 14, 2007 /Xinhua-PRNewswire...day announced the results,from its Phase II trial ...lmonary Disease (COPD), a respiratory disease,affe...l was conducted in 79 diagnosed COPD patients at 1...he trial was to,determine if subjects that were po...
...pany anticipates second quarter BLA filing for C1-... 2007 /PRNewswire-FirstCall/ -- Lev,Pharmaceutical...m,its pivotal U.S. Phase III trial of C1-esterase ...ditary angioedema (HAE). In the,acute study, which...tor in Hereditary Angioedema Nanofiltration Genera...
Other Medicine Technology:Pharmaxis Reports Phase II Results for Aridol in COPD 2Pharmaxis Reports Phase II Results for Aridol in COPD 3Pharmaxis Reports Phase II Results for Aridol in COPD 4Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 2Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 3Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 4Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III,Trial for Hereditary Angioedema 5
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: